Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zepp Health (ZEPP) EBITDA (2016 - 2025)

Zepp Health has reported EBITDA over the past 10 years, most recently at -$3.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 56.69% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached -$29.2 million, up 38.13%, while the annual FY2025 figure was -$8.9 million, 81.24% up from the prior year.
  • EBITDA for Q4 2025 was -$3.9 million at Zepp Health, down from -$884000.0 in the prior quarter.
  • Over five years, EBITDA peaked at $11.1 million in Q2 2021 and troughed at -$24.5 million in Q1 2022.
  • A 5-year average of -$7.7 million and a median of -$9.4 million in 2024 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: soared 733.13% in 2021 and later tumbled 1527.8% in 2024.
  • Year by year, EBITDA stood at $1.6 million in 2021, then plummeted by 751.55% to -$10.3 million in 2022, then surged by 106.08% to $626000.0 in 2023, then tumbled by 1527.8% to -$8.9 million in 2024, then surged by 56.69% to -$3.9 million in 2025.
  • Business Quant data shows EBITDA for ZEPP at -$3.9 million in Q4 2025, -$884000.0 in Q3 2025, and -$6.1 million in Q2 2025.